Dianthus Therapeutics (DNTH) grants CFO 150,000 stock options at $52.46

Rhea-AI Filing Summary

Dianthus Therapeutics reported a new equity award to its EVP, CFO & CBO, Ryan Savitz. On February 3, 2026, he received a stock option covering 150,000 shares of common stock with an exercise price of $52.46 per share and no cost at grant.

The option expires on February 3, 2036 and the underlying shares will vest in equal monthly installments over four years after January 1, 2026, as long as he continues serving the company on each vesting date. All 150,000 derivative securities are reported as directly owned following the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Savitz Ryan

Role EVP, CFO & CBO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	150,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savitz Ryan

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CFO & CBO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$52.46	02/03/2026		A		150,000		(1)	02/03/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Ryan Savitz	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dianthus Therapeutics (DNTH) report in this Form 4?

Dianthus Therapeutics reported a grant of stock options to executive Ryan Savitz. He received options for 150,000 shares of common stock at a $52.46 exercise price, expiring February 3, 2036, as part of his equity compensation package.

Who is the insider in this Dianthus Therapeutics (DNTH) Form 4 filing?

The insider is Ryan Savitz, who serves as EVP, CFO & CBO of Dianthus Therapeutics. The filing shows he was granted a stock option for 150,000 shares of common stock on February 3, 2026, reported as directly owned.

How many stock options were granted to Dianthus executive Ryan Savitz?

Ryan Savitz was granted a stock option covering 150,000 shares of Dianthus common stock. All 150,000 derivative securities are shown as beneficially owned following the transaction, with the award reported as a direct holding under his name.

What is the exercise price and term of the Dianthus (DNTH) options granted?

The stock option granted to Ryan Savitz has an exercise price of $52.46 per share. The option expires on February 3, 2036, giving him a ten-year term from the grant date to exercise, subject to vesting and continued service conditions.

What is the vesting schedule for the Dianthus options granted to Ryan Savitz?

The underlying shares vest in equal monthly installments over four years after January 1, 2026. Vesting occurs only if Ryan Savitz continues his service with Dianthus Therapeutics on each monthly vesting date, according to the footnote description.

Does the Form 4 show a purchase or sale of Dianthus (DNTH) shares by the executive?

The Form 4 shows an award of stock options coded as an acquisition (A), not a market sale. The option was granted at a derivative price of $0, with a $52.46 per share exercise price if exercised in the future.